Clinical trialNCT00767416CompletedPhase 1/PHASE2Interventional

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children

SponsorMedImmune LLCEnrollment116Healthy

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary objective of this study is to describe the 28-day post-final dose safety and tolerability of three doses of MEDI-559 at 10\^5 FFU when administered to healthy RSV seronegative children 1 to \<24 months of age.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Joseph Sliman, M.D.
MedImmune LLC
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

76 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Puerto Rico

Research Site
Caguas, Puerto Rico

United States

Research Site
Greenville, Alabama, United States
Research Site
Huntsville, Alabama, United States
Research Site
Mobile, Alabama, United States
Research Site
Conway, Arkansas, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Anaheim, California, United States
Research Site
Cypress, California, United States
Research Site
Downey, California, United States
Research Site
Huntington Beach, California, United States
Research Site
Lakewood, California, United States
Research Site
Long Beach, California, United States
Research Site
Los Angeles, California, United States
Research Site
Los Angeles, California, United States
Research Site
Paramount, California, United States
Research Site
San Diego, California, United States
Research Site
Santa Ana, California, United States
Research Site
Thornton, Colorado, United States
Research Site
Hartford, Connecticut, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Miami, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Orange City, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Dalton, Georgia, United States
Research Site
Chicago, Illinois, United States
Research Site
Fishers, Indiana, United States
Research Site
New Albany, Indiana, United States
Research Site
South Bend, Indiana, United States
Research Site
Ames, Iowa, United States
Research Site
Bardstown, Kentucky, United States
Research Site
Lexington, Kentucky, United States
Research Site
Lexington, Kentucky, United States
Research Site
Louisville, Kentucky, United States
Research Site
Louisville, Kentucky, United States
Research Site
Paducah, Kentucky, United States
Research Site
Metarie, Louisiana, United States
Research Site
Fredrick, Maryland, United States
Research Site
Boston, Massachusetts, United States

36 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

MEDI-559

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2008
Primary completion: 31 Dec 2011
Completion: 31 Dec 2011
Last update posted: 20 Jul 2016
Registered enrollment: 116
Registry id: NCT00767416

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.